OBJECTIVE: The aim: To research differences of interleukin (IL)-17 and IL-23 serum levels in patients with Alzheimer's disease, vascular dementia and mild cognitive impairment. PATIENTS AND METHODS: Material and methods: Serum levels of IL-17 and IL-23 were measure by ELISA for 15 patients with Alzheimer's disease, 14 with vascular dementia, 30 with mild cognitive impairment and 30 control individuals without cognitive impairment. RESULTS: Results: Serum concentrations of IL-17 were significantly higher in Alzheimer's disease patients (P=0.0023) than control, in vascular dementia no significant differences(P=0.4154). Level of IL-23 was significantly higher than control in Alzheimer's disease patients (P=0.0170) and vascular dementia (P=0.0002), but in Alzheimer's disease it was in 12.5 time higher. In total mild cognitive impairment patients no significant differences in interleukin concentration with control, but significant differences observed for amnestic form in IL-17 (P=0.0436) and IL-23 (P=0.0019). CONCLUSION: Conclusions: IL-17 and IL-23 level significant higher in Alzheimer's disease patients compared with control and vascular dementia. From mild cognitive impairment levels of detectable interleukins was higher in amnestic form that may be early marker of progression in Alzheimer's disease.
OBJECTIVE: The aim: To research differences of interleukin (IL)-17 and IL-23 serum levels in patients with Alzheimer's disease, vascular dementia and mild cognitive impairment. PATIENTS AND METHODS: Material and methods: Serum levels of IL-17 and IL-23 were measure by ELISA for 15 patients with Alzheimer's disease, 14 with vascular dementia, 30 with mild cognitive impairment and 30 control individuals without cognitive impairment. RESULTS: Results: Serum concentrations of IL-17 were significantly higher in Alzheimer's disease patients (P=0.0023) than control, in vascular dementia no significant differences(P=0.4154). Level of IL-23 was significantly higher than control in Alzheimer's disease patients (P=0.0170) and vascular dementia (P=0.0002), but in Alzheimer's disease it was in 12.5 time higher. In total mild cognitive impairment patients no significant differences in interleukin concentration with control, but significant differences observed for amnestic form in IL-17 (P=0.0436) and IL-23 (P=0.0019). CONCLUSION: Conclusions: IL-17 and IL-23 level significant higher in Alzheimer's disease patients compared with control and vascular dementia. From mild cognitive impairment levels of detectable interleukins was higher in amnestic form that may be early marker of progression in Alzheimer's disease.